KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Total Debt (2016 - 2025)

Halozyme Therapeutics (HALO) has disclosed Total Debt for 13 consecutive years, with $2.1 billion as the latest value for Q4 2025.

  • On a quarterly basis, Total Debt rose 42.29% to $2.1 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $2.1 billion, a 42.29% increase, with the full-year FY2025 number at $2.1 billion, up 42.29% from a year prior.
  • Total Debt was $2.1 billion for Q4 2025 at Halozyme Therapeutics, up from $1.5 billion in the prior quarter.
  • In the past five years, Total Debt ranged from a high of $2.1 billion in Q4 2025 to a low of $9.9 million in Q2 2025.
  • A 5-year average of $1.1 billion and a median of $1.5 billion in 2023 define the central range for Total Debt.
  • Peak YoY movement for Total Debt: skyrocketed 3014.45% in 2021, then tumbled 99.34% in 2025.
  • Halozyme Therapeutics' Total Debt stood at $876.7 million in 2021, then skyrocketed by 71.8% to $1.5 billion in 2022, then decreased by 0.45% to $1.5 billion in 2023, then increased by 0.44% to $1.5 billion in 2024, then surged by 42.29% to $2.1 billion in 2025.
  • Per Business Quant, the three most recent readings for HALO's Total Debt are $2.1 billion (Q4 2025), $1.5 billion (Q3 2025), and $9.9 million (Q2 2025).